AstraZeneca is now the latest drugmaker to reveal a vaccine that could potentially help end the global health crisis.

It announced Monday (November 23) the vaccine - which was developed by Britain's the University of Oxford - could be 90% effective, and works in different age groups.

AstraZeneca and Oxford also confirmed no-one who took part in the experiment showed any serious side effects.

They found the vaccine was 90% effective when taken as a half dose followed by a full dose a month later.

Although that went down to 62% when given as two full doses at least one month apart.

The combined analysis from both dosing regimens produced an average efficacy of 70%.

The director of the Oxford Vaccine Group - Andrew Pollard - called the results 'intriguing'.

He said more work needs to be done on the finding that an initial half dose of the shot offers more protection.

AstraZeneca's data is yet another breakthrough in the race to end the health crisis that has killed 1.4 million people and caused severe economic pain.

In recent weeks, U.S. drugmaker Pfizer and its German partner BioNTech showed their treatment was 95% effective.

While U.S. rival Moderna also revealed data showing its own vaccine was close to 95% effective.